Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9C0B1
UPID:
FTO_HUMAN
Alternative names:
Fat mass and obesity-associated protein; U6 small nuclear RNA (2'-O-methyladenosine-N(6)-)-demethylase FTO; U6 small nuclear RNA N(6)-methyladenosine-demethylase FTO; mRNA (2'-O-methyladenosine-N(6)-)-demethylase FTO; mRNA N(6)-methyladenosine demethylase FTO; tRNA N1-methyl adenine demethylase FTO
Alternative UPACC:
Q9C0B1; A2RUH1; B2RNS0; Q0P676; Q7Z785
Background:
Alpha-ketoglutarate-dependent dioxygenase FTO, known for its roles in RNA demethylation and energy homeostasis, is pivotal in regulating fat mass and adipogenesis. It specifically targets N(6)-methyladenosine (m6A) in various RNA species, influencing mRNA expression and stability. This protein also plays a crucial role in the differentiation of adipocytes into brown or white fat cells, affecting body size and fat accumulation.
Therapeutic significance:
FTO's involvement in severe polymalformation syndrome and obesity highlights its potential as a therapeutic target. Understanding the role of Alpha-ketoglutarate-dependent dioxygenase FTO could open doors to potential therapeutic strategies for these conditions, especially given its regulatory role in fat mass and energy homeostasis.